SLC5A2 and hydrops fetalis: To our knowledge, this is one of the first systematic reviews to systematically synthesize evidence from both RCTs and real-world studies specifically evaluating the efficacy, safety, and clinical applicability of SGLT2 inhibitors in non-diabetic patients with HF across different phenotypes.